26th week of 2016 patent applcation highlights part 24 |
Patent application number | Title | Published |
20160185755 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS - The invention refers to compounds of general formula (I) | 2016-06-30 |
20160185756 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS - Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer. | 2016-06-30 |
20160185757 | INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF - Agents of formulas (I)/(II)/(III) for modulating methyl modifying enzymes, compositions and uses thereof are provided herein. | 2016-06-30 |
20160185758 | 2-(Pyridin-2-yl)-1, 7-Diaza-Spiro [4.4] Nonane-6-One Compound as Voltage-Gated Sodium Channel Modulator - The invention relates to spiro derivatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation. | 2016-06-30 |
20160185759 | NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF - The patent discloses novel indazole compounds of general formula 1 and analogues thereof, use thereof for the treatment of diabetes, diabetic complications, cardiovascular dysfuntion or related diseases, pharmaceutical compositions comprising them and processes for their preparation. | 2016-06-30 |
20160185760 | PROCESS FOR THE PREPARATION OF MALIC ACID SALT OF SUNITINIB - The present invention relates to a process of preparation of malic acid salt of sunitinib.(I). | 2016-06-30 |
20160185761 | Compounds for Enhancing the Cognitive Function - The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline. | 2016-06-30 |
20160185762 | METHOD FOR PRODUCING TRIS-AZIRIDINOMETHANE - A process for preparing trisaziridinomethane (I) | 2016-06-30 |
20160185763 | LIQUID CRYSTAL STABILIZER, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME - A liquid crystal stabilizer according to an exemplary embodiment of the present invention includes at least one of the compounds represented by the following Chemical Formulae 1 and 2. | 2016-06-30 |
20160185764 | PREPARATION AND USE OF 7A-AMIDE SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS - The present invention relates to bicyclic himbacine derivatives of the formula | 2016-06-30 |
20160185765 | ORGANIC METAL COMPLEX, LIGHT EMITTING MATERIAL, DELAYED FLUORESCENT MATERIAL, AND ORGANIC LIGHT EMITTING DEVICE - An organic metal complex represented by the following general formula is useful as a light emitting material for an organic electroluminescent device and others. X represents O, S or —N(R | 2016-06-30 |
20160185766 | Novel Salts of Raltegravir - Provided herein are novel salts of raltegravir, viz., meglumine salt, erbumine salt, ammonium salt, tris salt and L-arginine salt of raltegravir and processes for their preparation. | 2016-06-30 |
20160185767 | SOLID ORAL DOSAGE FORMULATION OF HCV INHIBITOR IN THE AMORPHOUS STATE - Described herein are solid oral dosage forms containing Compound (1) or a pharmaceutically acceptable salt thereof (Formula 1), wherein Compound (1) is in the amorphous state. Also described are solid oral dosage forms comprising a composition of Compound (1) in the amorphous state and one or more pharmaceutically acceptable excipients. Compound (1) is a specific inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Thus, also described herein are methods for using the described solid oral dosage forms in the treatment of HCV infection. Also described are processes for the manufacture of the solid oral dosage forms. | 2016-06-30 |
20160185768 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS - The present invention is directed to thiazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thiazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2016-06-30 |
20160185769 | Bromodomain Inhibitors - The present invention provides for compounds of formula (I). wherein R | 2016-06-30 |
20160185770 | SALTS, CO-CRYSTALS, AND POLYMORPHS OF AN ANXIOLYTIC COMPOUND - The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof. | 2016-06-30 |
20160185771 | Conjugate of Benzofuranone and Indole or Azaindole, and Preparation and Uses Thereof - The present invention relates to an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis/trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for treating or preventing diseases such as glucose metabolic disorder, inflammatory or autoimmune disease, neurodegenerative disease, a mental illness, tissue proliferation disease or tumors. | 2016-06-30 |
20160185772 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF - Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. | 2016-06-30 |
20160185773 | BICYCLIC INHIBITORS - The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein A, B, W, X and Y are as defined herein. | 2016-06-30 |
20160185774 | Anti-Infective Compounds - The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis. | 2016-06-30 |
20160185775 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF - The present application relates to novel pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders. | 2016-06-30 |
20160185776 | IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR - Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF- | 2016-06-30 |
20160185777 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS - Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. | 2016-06-30 |
20160185778 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS - Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. | 2016-06-30 |
20160185779 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS - Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. | 2016-06-30 |
20160185780 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. | 2016-06-30 |
20160185781 | 1,9-DIAZAPHENALENE DERIVATIVE AND PROCESS FOR MANUFACTURING THE SAME - A 1,9-diazaphenalene derivative is represented by | 2016-06-30 |
20160185782 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION - This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer. | 2016-06-30 |
20160185783 | ACC INHIBITORS AND USES THEREOF - The present invention provides for compounds of formula I as acetyl-CoA carboxylase (ACC) inhibitors. The ACC inhibitors are useful for the prevention or treatment of metabolic syndrome, including obesity, dyslipidemia and hyperlipidemia in humans. The inhibitor compounds are also capable of inhibiting the ACC enzyme found in plants, parasites and bacteria. | 2016-06-30 |
20160185784 | BICYCLIC UREAS AND THIADIAZOLIDINE-1, 1-DIOXIDES AS CETP INHIBITORS - Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is —C(═O) or —S(O) | 2016-06-30 |
20160185785 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS - The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: | 2016-06-30 |
20160185786 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS - The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: | 2016-06-30 |
20160185787 | NEW STABLE SALT OF 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID - The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy. | 2016-06-30 |
20160185788 | PROCESS FOR PREPARING OXYCODONE COMPOSITIONS - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 2016-06-30 |
20160185789 | PROCESS FOR PREPARING OXYCODONE COMPOSITIONS - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 2016-06-30 |
20160185790 | PROCESS FOR PREPARING OXYCODONE COMPOSITIONS - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 2016-06-30 |
20160185791 | DERIVATIVES OF UNCIALAMYCIN, METHODS OF SYNTHESIS AND THEIR USE AS ANTITUMOR AGENTS - In one aspect, the present disclosure provides new analogs of uncialamycin of formulae (I) and (II). The present disclosure also provides novel synthetic pathways to obtaining uncialamycin and analogs thereof. Additionally, the present disclosure also describes methods of use of uncialamycin and analogs thereof. In another aspect, the present disclosure provides antibody-drug conjugates comprising the compounds of formulae (I) and (II). | 2016-06-30 |
20160185792 | METHOD FOR THE PURIFICATION OF EPOTHILONES VIA CRYSTALLIZATION - The present invention provides a new method of separating epothilones from one another that can be used on an industrial scale for the selective enrichment of epothilone and to provide a crystalline solid of enhanced purity, which can be used for the production of pharmaceutical preparations without using normal or reverse-phase chromatography or any energy input via distillation apparatus, wherein the new method comprises the steps:
| 2016-06-30 |
20160185793 | METHOD FOR THE PURIFICATION OF EPOTHILONES VIA CRYSTALLIZATION - The present invention provides a new method of separating epothilones from one another that can be used on an industrial scale for the selective enrichment of epothilone and to provide a crystalline solid of enhanced purity, which can be used for the production of pharmaceutical preparations without using normal or reverse-phase chromatography or any energy input via distillation apparatus, wherein the new method comprises the steps:
| 2016-06-30 |
20160185794 | METHOD FOR SELECTIVELY PREPARING EVOGLUCOSENONE (LGO) AND OTHER ANHYDROSUGARS FROM BIOMASS IN POLAR APROTIC SOLVENTS - A method to produce 5-hydroxymethylfurfural (HMF) is described in which a reactant including cellulose, lignocellulose, or a combination thereof, in a reaction mixture of a polar, aprotic solvent and an acid is reacted for a time, at a temperature, and at a hydrogen ion concentration wherein at least a portion of the cellulose or lignocellulose present in the reactant is converted to HMF. The reaction mixture is initially substantially devoid of water. As the reaction proceeds, dehydration of intermediates causes the water concentration in the reaction mixture to rise to no more than about 2.0 wt % water. | 2016-06-30 |
20160185795 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS - The invention provides novel compounds having the general formula (I) | 2016-06-30 |
20160185796 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY - The invention provides a compound of Formula I, | 2016-06-30 |
20160185797 | ALKYNYL ALCOHOLS AND METHODS OF USE - The invention relates to compounds of Formula (0): | 2016-06-30 |
20160185798 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS - This invention relates to compounds of formula I, | 2016-06-30 |
20160185799 | ACC INHIBITORS AND USES THEREOF - The present invention provides compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same. | 2016-06-30 |
20160185800 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein. | 2016-06-30 |
20160185801 | 5-HT3 RECEPTOR ANTAGONISTS - The present invention provides compounds of the formula: | 2016-06-30 |
20160185802 | ANTIMICROBIAL COMPOSITE MATERIAL AND METHOD FOR FABRICATING THE SAME - An antimicrobial composite material and a method for fabricating the same are provided. The antimicrobial composite material includes a porous material, a chelating agent, and a multivalent metal ion. The chelating agent is chemically bonded to the porous material, and the multivalent metal ion is chemically bonded to the chelating agent. | 2016-06-30 |
20160185803 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES - The present disclosure relates generally to a process for the synthesis of 1,4,7,10-tetraazacyclododecane ligands, chelates, and derivatives thereof. In particular, the present disclosure is directed to a process for the synthesis of 1,4,7,10-tetraaza-1,4,7,10-tetrakis(carboxymethyl)cyclododecane (DOTA) ligands, corresponding DOTA-metal chelates, and various derivatives thereof. | 2016-06-30 |
20160185804 | SILANE AND SILICIC ACID (HETERO)POLYCONDENSATE HAVING AROMATIC COMPOUNDS LINKED VIA COUPLING GROUPS WHICH ARE SUITABLE AS OR FOR MATRIX SYSTEMS HAVING HIGH TRANSLUCENCY AND GOOD MECHANICAL PROPERTIES - The present invention relates to compounds and silicic acid (hetero)polycondensates comprising structures of formulas (1) and/or (2), | 2016-06-30 |
20160185805 | PROBE FOR IMAGING PARP-1 ACTIVITY - Provided are embodiments of a small molecule tracer for positron emission tomography (PET) imaging of the enzyme activity of PARP-1 that is responsible for DNA-damage sensing and critically involved in radiation therapy and some chemotherapy response mechanisms. These PARP-1 tracers are derivatives of nicotinamide adenine dinucleotide (NAD), which is the natural substrate for PARP-1. Provided are NAD derivatives that include a linker moiety to which may be attached a label moiety such as a PET detectable fluorine to generate a 6N-(triazo-PEG2- | 2016-06-30 |
20160185806 | PROCESS FOR OBTAINING METAL-ORGANIC MATERIALS WITH STRUCTURE TYPE MIL-101 (Cr) AND MIL-101-Cr-Mx+ - The present invention relates to a process for obtaining materials with Metal Organic atomic structure and called MOF (MOF: Metal Organic Framework) type MIL-101 (Cr) and MIL-101-Cr-M | 2016-06-30 |
20160185807 | Manganese Complexes And Use Thereof For Preparing Thin Films - Manganese complexes, methods of making the same, and use thereof in thin film deposition, such as CVD and ALD are provided herein. | 2016-06-30 |
20160185808 | PLATINUM DERIVATIVES FOR HYDROPHOBIC FORMULATIONS - New derivatives of a Pt (II) complex provided which are liposoluble and useful as anticancer agents. Also disclosed are platinum II complexes in delivery systems such as liposomes, emulsions, nanoemulsions, and lipid excipients. | 2016-06-30 |
20160185809 | METHOD FOR LIGNIN RECOVERY - The present invention primarily relates to a method for isolating lignin, preferably unmodified lignin, from a mixture, in particular a pulping slurry, containing lignin, a cellulose solvent, a cellulose precipitant, minerals and optionally (residual) cellulose and/or hemicellulose and/or hydrolysation products thereof, comprising or consisting of the following steps:
| 2016-06-30 |
20160185810 | RESIN COMPOSITIONS COMPRISING LIGNIN DERIVATIVES - The present invention provides derivatives of native lignin having a certain ethoxy content. Surprisingly, it has been found that phenolic resins comprising derivatives of native lignin having certain ethoxy contents have acceptable performance characteristics such as bond-strength. | 2016-06-30 |
20160185811 | Spiroannulated nucleosides and process for the preparation thereof - We claim a simple strategy for the synthesis of a collection of C(3′)-spirodihydroisobenzo-furannulated and C(3′)-spirodihydroisobenzo-furannulated nucleosides featuring a [2+2+2]-cyclotrimerization as the key reaction. The cyclotrimerization reactions are facile with the unprotected nucleosides having a diyne unit. When both alkynes of the diyne are terminal, the regioselectivity is poor. However, when one of the terminal alkynes is additionally substituted, the cyclotrimerizations are highly diastereoselective. Since the key bicycloannulation is the final step, this strategy provides flexibility in terms of the alkynes and is thus amenable for the synthesis of a focussed small molecule library. | 2016-06-30 |
20160185812 | PROCESS FOR SYNTHESIZING HIGHLY OPTICALLY ACTIVE 1,3-DISUBSTITUTED ALLENES - The present invention relates to a process for efficiently synthesizing highly optically active 1,3-disubstituted allenes, i.e., a one-step process for preparing highly optically active 1,3-disubstituted allenes by using a functionalized terminal alkyne, an aldehyde and a chiral α,α-diphenyl prolinol as reactants under the catalysis of a divalent copper salt. The operation of the process is simple, and the raw materials and reagents are readily available. The process has a broad-spectrum of substrates and a good compatibility for a wide variety of functional groups such as glycosidic units, primary alcohols, secondary alcohols, tertiary alcohols, amides, malonates, etc., and does not require the protection for the functional groups. The obtained axially chiral allene has a moderate to high yield and a good diastereoselectivity or enantioselectivity. | 2016-06-30 |
20160185813 | RECOVERY OF STEVIOL GLYCOSIDES - The present invention relates a process for the recovery of one or more steviol glycosides from a steviol glycoside-containing fermentation broth, which method comprises (a) providing a fermentation broth comprising one or more steviol glycosides and one or more non-steviol glycoside components; (b) separating the liquid phase of the broth from the solid phase of the broth; (c) providing an adsorbent resin; (d) contacting the liquid phase of the broth with the adsorbent resin in order to separate at least a portion of the one or more steviol glycosides from the non-steviol glycoside components, thereby to recover one or more steviol glycosides from the fermentation broth containing one or more steviol glycosides. The invention also relates to a purified steviol glycoside composition prepared using such a process. | 2016-06-30 |
20160185814 | VIRUS DETECTION - The invention provides methods and materials for use in the detection of influenza viruses which utilise a nanoparticle, for example gold nanoparticle, probe comprising a plurality of glycoconjugate ligands, each glyconjugate ligand (GL) having a plurality of sialic-acid containing recognition group (Y) coupled to the nanoparticle via a multivalent core (X), wherein the multivalent core (X) is a trivalent core, whereby there are 3 recognition groups per ligand, wherein the recognition groups on the bioconjugate specifically bind to the hemagglutinin on the target influenza virus. The probes may include further ligands bound to the nanoparticle which do not bind specifically to an influenza virus—for example polyethylene glycol groups. These can modulate density of the glycoconjugate ligand on the surface of the nanoparticle. Binding of probes is detected by a plasmonic signal which is specific to the influenza virus. | 2016-06-30 |
20160185815 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula I, | 2016-06-30 |
20160185816 | METHOD OF PURIFYING POLYPEPTIDES - The present invention relates to improved processes for purifying polypeptides of interest by increasing the amount of a polypeptide of interest bound to an ion-exchange matrix relative to the amount of one or more impurities bound to the ion-exchange matrix. This effect is achieved by adding a chemical compound in the process which by also binding to the ion-exchange matrix due to a charge that is opposite to the charge of the ion-exchange matrix, reduces the binding of impurities more than the binding of the polypeptide of interest. | 2016-06-30 |
20160185817 | PURIFICATION OF CHIMERIC FVIII MOLECULES - The invention is directed to methods of purifying a chimeric protein comprising subjecting the chimeric protein to a factor VIII-specific affinity chromatography, and subjecting the chimeric protein to an AEX chromatography; wherein the chimeric protein comprises a factor VIII protein or a fragment thereof. The chimeric protein purified by the present methods shows improved factor VIII activity. | 2016-06-30 |
20160185818 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES - Both JNK and LRRK2 are associated with Parkinson's disease (PD), myocardial infarction (MI), and other medical disorders. Here we report a reasonably selective and potent kinase inhibitors (e.g., compounds 6 and 10) that bound to both JNK and LRRK2 (a dual inhibitor). A bidentate-binding strategy that simultaneously utilized the ATP hinge binding and a unique protein surface site outside of the ATP pocket was applied to the design and identification of this kind of inhibitor. Compound 6 was a potent JNK3 and modest LRRK2 dual inhibitor with an enzyme IC50 value of 12 nM and 99 nM (LRRK2-G2019S), respectively. 6 also exhibited good cell potency, inhibited LRRK2:G2019S induced mitochondrial dysfunction in SHSY5Y cells, and was demonstrated to be reasonably selective against a panel of 116 kinases from representative kinase families. | 2016-06-30 |
20160185819 | PEPTIDES FOR THE STIMULATION OF COLLAGEN FORMATION - The present invention relates to a compound of formula (I) and to compositions comprising said compound, as well as the use of said compound and/or said compositions in the cosmetic treatment of skin and/or hair, and to the use thereof for inducing the formation of collagen. | 2016-06-30 |
20160185820 | PROTRANSDUZIN B, A GENE TRANSFER ENHANCER - An N-terminally protected peptide having the sequence | 2016-06-30 |
20160185821 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES - The invention relates generally to the synthesis of modified amino acids and modified peptides in the presence of cyclometalated catalysts. The invention has utility in the fields of catalysis, organic synthesis, polymer chemistry, and industrial and fine chemicals chemistry. | 2016-06-30 |
20160185822 | CORTISTATIN ANALOGUES FOR THE TREATMENT OF INFLAMMATORY AND/OR IMMUNE DISEASES - The invention relates to cortistatin analogues and their uses. The compounds of the invention are peptide ligands with potential application in the diagnosis, prevention or therapy of those pathologies where receptors capable of binding to cortistatin, specific or shared with other molecules such as somatostatin and/or ghrelin (GHSR), are expressed, being in addition more stable in serum than cortistatin. | 2016-06-30 |
20160185823 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS - The present invention provides antimicrobial polymyxin compounds of the following formula I: | 2016-06-30 |
20160185824 | BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING - There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β-sheet tape-like substructure wherein the material comprises a pair of self assembling complementary polypeptides. | 2016-06-30 |
20160185825 | ENGINEERED OUTER DOMAIN (EOD) OF HIV GP120 AND MUTANTS THEREOF - The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings. | 2016-06-30 |
20160185826 | VIRUS-LIKE PARTICLE VACCINES - The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions. | 2016-06-30 |
20160185827 | VACCINES FOR PREVENTING MENINGOCOCCAL INFECTIONS - The present invention stems from the finding that the interaction between the β2 adrenoceptor (β2AP) and type IV pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier. The invention therefore pertains to a vaccine for preventing the spreading of meningococci into the meningeal space, wherein said vaccine allows the production of antibodies inhibiting the interaction between the type IV pilus-associated proteins and the β2AP. | 2016-06-30 |
20160185828 | Genetic Reprogramming of Bacterial Biofilms - Described herein are methods and compositions relating to engineered curii fibers, e.g. CsgA polypeptide. In some embodiments, the methods and compositions described herein relate to functionalized biofilms. In one aspect, described herein is an engineered CsgA polypeptide, comprising a CsgA polypeptide with a C-terminal display tag flanking the CsgA polypeptide; wherein the display tag comprises an activity polypeptide and a linker sequence. In some embodiments, the display tag and/or the activity polypeptide comprises a polypeptide selected from the group consisting of metal binding domain (MBD); Spy Tag; graphene binding (GBP); carbon nanotube binding (CBP); gold binding (A3); CT43; FLAG; Z8; E14; QBP1; CLP12; and AFP8. | 2016-06-30 |
20160185829 | Toxoid Peptides Derived from Phenol Soluble Modulin, Delta Toxin, Superantigens, and Fusions Thereof - The present disclosure provides immunogenic compositions useful in prevention and treatment of | 2016-06-30 |
20160185830 | AXMI440 TOXIN GENE AND METHODS FOR ITS USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:3-6, or the nucleotide sequence set forth in SEQ ID NO: 1 or 2, as well as variants and fragments thereof. | 2016-06-30 |
20160185831 | NUCLEIC ACIDS FOR TREATMENT OF ALLERGIES - The present invention provides DNA vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs. | 2016-06-30 |
20160185832 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS RELATED TO CEP290 - Compositions are provided that comprise a recombinant vector carrying a nucleic acid sequence encoding a fragment of CEP290 lacking all or part of its N-terminal and C-terminal inhibitory regions, under the control of regulatory sequences which express the product of said gene in a selected cell of a mammalian subject, and a pharmaceutically acceptable carrier. These and other compositions are disclosed with are useful in methods for treating a mammalian subject having a disease associated with a CEP290 mutation, such as Lebers Congenital Amaurosis. | 2016-06-30 |
20160185833 | PEPTIDES - The present invention provides a peptide at least partially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoantibody formation in Graves' Disease. | 2016-06-30 |
20160185834 | PROTEIN ENGINEERED SYSTEMS FOR DELIVERY OF MOLECULES - Provided are compositions and methods for efficient delivery of polynucleotides and/or small molecules to or into cells. The compositions comprises a peptide which as an excess positive charge and self assembles into homopentamers. The homopentamers can non-covalently bind polynucleotides. When encapsulated in lipid systems, such as liposomes, the lipoproteoplexes so formed, are capable of delivering both nucleic acids and small molecules to cells. | 2016-06-30 |
20160185835 | IMMUNE SYSTEM MEDIATOR - The present invention discloses an isolated nucleic acid molecule encoding an ISRAA polypeptide comprising at least 70% homology to the sequence represented by the nucleotide sequence SEQ ID NO: 1. Also disclosed is a recombinant expression vector comprising said nucleic acid molecule and an isolated polypeptide molecule encoded by said nucleic acid molecule. | 2016-06-30 |
20160185836 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS WITH FOLLISTATIN POLYPEPTIDES - The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use. | 2016-06-30 |
20160185837 | GIP AND GLP-1 RECEPTOR DUAL-AGONISTS FOR THE TREATMENT OF DIABETES - This disclosure provides GIP/GLP-1 dual agonist polypeptides for the treatment of hypoglycemic conditions, e.g., type-2 diabetes. | 2016-06-30 |
20160185838 | Compositions and Methods for Diagnosing and Treating Cancer - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth. | 2016-06-30 |
20160185839 | POLYMERIC FORMS OF H-NOX PROTEINS - The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers. | 2016-06-30 |
20160185840 | RNA-CODED ANTIBODY - The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method. | 2016-06-30 |
20160185841 | METHOD FOR PURIFYING ANTIBODIES USING PBS - Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris). | 2016-06-30 |
20160185842 | 14-3-3 Antagonists for the Prevention and Treatment of Arthritis - The invention provides compositions and methods for treating arthritis. | 2016-06-30 |
20160185843 | TREATING ALCOHOL-MEDIATED DISORDERS BY INHIBITION OF RGS6 - The invention provides RGS6 antagonists and methods for their use in treating the effects of alcohol consumption. | 2016-06-30 |
20160185844 | MODULATION OF SYNAPTIC MAINTENANCE - C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease. | 2016-06-30 |
20160185845 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF DISEASES CHARACTERIZED BY VASCULAR LEAK, HYPOTENSION, OR A PROCOAGULANT STATE - Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed. | 2016-06-30 |
20160185846 | ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS - The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same. | 2016-06-30 |
20160185847 | USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS - A composition includes monoclonal antibodies directed against a circulating proinflammatory cytokine, the antibodies having a high affinity for the FcγRIIIa receptor (CD16), in particular the fucose level of all of the antibodies of the composition being less than 60%, and preferably less than 50%, and in particular, the galactosylation level of all of the antibodies of the composition being at least 60%, for the use thereof in the context of the prevention or treatment of the early phases of inflammation. A composition including monoclonal antibodies directed against a circulating bacterial toxin, having an improved affinity for the FcγRIIIa receptor (CD16) with respect to antibodies directed against the bacterial toxin, produced in the CHO cell line, for the use thereof in the context of the prevention or treatment of the early phases of a bacterial infection linked to the release of the toxin is also described. | 2016-06-30 |
20160185848 | METHODS FOR MODULATING THE GLYCOSYLATION PROFILE OF RECOMBINANT PROTEINS USING SUGARS - The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of recombinant proteins expressed in host cells. | 2016-06-30 |
20160185849 | MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING IDIOPATHIC INFLAMMATORY BOWEL DISEASE - Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase. | 2016-06-30 |
20160185850 | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF ALPHA - The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed. | 2016-06-30 |
20160185851 | ANTIBODIES TO INTERLEUKIN-6 AND USE THEREOF - The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer. | 2016-06-30 |
20160185852 | ANTI-NOTCH3 ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3. | 2016-06-30 |
20160185853 | CANCER TREATMENT USING ANTIBODIES THAT BIND CELL SURFACE GRP78 - This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting cell surface GRP78 expressed on tumor cells, tumor endothelial cells, and tumor initiating cancer cells. These anti-GRP78 antibodies, or antigen-binding fragments thereof, have a high affinity for GRP78 and are less immunogenic compared to their unmodified parent antibodies in a given species, e.g., a human, and function to inhibit GRP78. Importantly, these isolated novel antibodies and antigen-binding fragments thereof, attenuate PI3K signaling and promote apoptosis in tumor cells, while leaving normal cells unaffected. The antibodies and antigen-binding fragments are useful for UPR-targeted cancer therapeutic treatments. | 2016-06-30 |
20160185854 | AGENTS TARGETING CD138 AND USES THEREOF - Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells. | 2016-06-30 |